Quarterly report pursuant to Section 13 or 15(d)

NON-CONTROLLING INTEREST

v3.21.2
NON-CONTROLLING INTEREST
6 Months Ended
Jun. 30, 2021
Noncontrolling Interest [Abstract]  
Noncontrolling Interest Disclosure [Text Block]

NOTE 10 NON-CONTROLLING INTEREST

 

On November 7, 2018, the Company formed ViralClear for the purpose to pursue additional applications of the PURE EP™ signal processing technology outside of electrophysiology and subsequently in 2020 was repurposed to develop a broad-spectrum anti-viral agent that had potential against the COVID-19 virus. In late 2020, ViralClear again was repurposed back to pursuing additional applications of the PURE EP™ signal processing technology outside of cardiac electrophysiology.

 

As of June 30, 2021 and December 31, 2020, the Company had a majority interest in ViralClear of 69.95% and 70.21%, respectively.  

 

A reconciliation of the ViralClear Pharmaceuticals, Inc. non-controlling loss attributable to the Company:

 

Net loss attributable to the non-controlling interest for the three months ended June 30, 2021 (000’s):

 

Net loss

  $ (1,167

)

Average Non-controlling interest percentage of profit/losses

    30.0

%

Net loss attributable to the non-controlling interest

  $ (350

)

 

Net loss attributable to the non-controlling interest for the three months ended June 30, 2020 (000’s):

 

Net loss

  $ (13,111

)

Average Non-controlling interest percentage of profit/losses

    24.1

%

Net loss attributable to the non-controlling interest

  $ (3,158

)

 

Net loss attributable to the non-controlling interest for the six months ended June 30, 2021 (000’s):

 

Net loss

  $ (1,971

)

Average Non-controlling interest percentage of profit/losses

    29.9

%

Net loss attributable to the non-controlling interest

  $ (590

)

 

Net loss attributable to the non-controlling interest for the six months ended June 30, 2020 (000’s):

 

Net loss

  $ (20,732

)

Average Non-controlling interest percentage of profit/losses

    22.1

%

Net loss attributable to the non-controlling interest

  $ (4,586

)

 

The following table summarizes the changes in non-controlling interest for the six months ended June 30, 2021 (000’s):

 

Balance, December 31, 2020

  $ 802  

Allocation of equity to non-controlling interest due to equity-based compensation issued

    162  

Net loss attributable to non-controlling interest

    (590

)

Balance, June 30, 2021

  $ 374